Muhammad Junaid Ahsan1, Soban Ahmad2, Azka Latif3, Noman Lateef4, Mohammad Zoraiz Ahsan5, Waiel Abusnina3, Sandeep Nathan6, S Elissa Altin7, Dhaval S Kolte8, John C Messenger9, Mark Tannenbaum1, Andrew M Goldsweig4. 1. Division of Cardiovascular Medicine, Iowa Heart Center, Des Moines, IA, USA. 2. Department of Internal Medicine, East Carolina University, Greenville, NC, USA. 3. Division of Cardiovascular Medicine, Creighton University, Omaha, NE, USA. 4. Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 5. Department of Internal Medicine, Fatima Memorial Hospital, Pakistan. 6. Division of Cardiovascular Medicine, University of Chicago, Chicago, IL, USA. 7. Division of Cardiovascular Medicine, Yale University, New Haven, CT, USA. 8. Division of Cardiovascular Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 9. Division of Cardiology Medicine, University of Colorado, Aurora, CO, USA.
Abstract
BACKGROUND: In ST-elevation myocardial infarction (STEMI), transradial access (TRA) for percutaneous coronary intervention (PCI) is associated with less bleeding and mortality than transfemoral access (TFA). However, patients in cardiogenic shock (CS) are more often treated via TFA. The aim of this meta-analysis is to compare the safety and efficacy of TRA vs. TFA in CS. METHODS: Systematic review was performed querying PubMed, Google Scholar, Cochrane, and clinicaltrials.gov for studies comparing TRA to TFA in PCI for CS. Outcomes included in-hospital, 30-day and ≥1-year mortality, major and access site bleeding, TIMI3 (thrombolytics in myocardial infarction) flow, procedural success, fluoroscopy time, and contrast volume. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using random effects models. RESULTS: Six prospective and eight retrospective studies (TRA, n = 8032; TFA, n = 23 031) were identified. TRA was associated with lower in-hospital (RR 0.59, 95% CI 0.52-0.66, P < 0.0001), 30-day and ≥1-year mortality, as well as less in-hospital major (RR 0.41, 0.31-0.56, P < 0.001) and access site bleeding (RR 0.42, 0.23-0.77, P = 0.005). There were no statistically significant differences in post-PCI coronary flow grade, procedural success, fluoroscopy time, and contrast volume between TRA vs. TFA. CONCLUSIONS: In PCI for STEMI with CS, TRA is associated with significantly lower mortality and bleeding complications than TFA while achieving similar TIMI3 flow and procedural success rates.
BACKGROUND: In ST-elevation myocardial infarction (STEMI), transradial access (TRA) for percutaneous coronary intervention (PCI) is associated with less bleeding and mortality than transfemoral access (TFA). However, patients in cardiogenic shock (CS) are more often treated via TFA. The aim of this meta-analysis is to compare the safety and efficacy of TRA vs. TFA in CS. METHODS: Systematic review was performed querying PubMed, Google Scholar, Cochrane, and clinicaltrials.gov for studies comparing TRA to TFA in PCI for CS. Outcomes included in-hospital, 30-day and ≥1-year mortality, major and access site bleeding, TIMI3 (thrombolytics in myocardial infarction) flow, procedural success, fluoroscopy time, and contrast volume. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using random effects models. RESULTS: Six prospective and eight retrospective studies (TRA, n = 8032; TFA, n = 23 031) were identified. TRA was associated with lower in-hospital (RR 0.59, 95% CI 0.52-0.66, P < 0.0001), 30-day and ≥1-year mortality, as well as less in-hospital major (RR 0.41, 0.31-0.56, P < 0.001) and access site bleeding (RR 0.42, 0.23-0.77, P = 0.005). There were no statistically significant differences in post-PCI coronary flow grade, procedural success, fluoroscopy time, and contrast volume between TRA vs. TFA. CONCLUSIONS: In PCI for STEMI with CS, TRA is associated with significantly lower mortality and bleeding complications than TFA while achieving similar TIMI3 flow and procedural success rates.
Authors: Nnamdi Nwaejike; Andre Y Son; Chetan B Patel; Jacob N Schroder; Carmelo A Milano; Mani A Daneshmand Journal: Innovations (Phila) Date: 2017 Nov/Dec
Authors: Tomasz Tokarek; Artur Dziewierz; Krzysztof Plens; Tomasz Rakowski; Dariusz Dudek; Zbigniew Siudak Journal: Pol Arch Intern Med Date: 2021-03-19
Authors: Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker Journal: G Ital Cardiol (Rome) Date: 2016-10
Authors: András Vorobcsuk; Attila Kónyi; Dániel Aradi; Iván G Horváth; Imre Ungi; Yves Louvard; András Komócsi Journal: Am Heart J Date: 2009-11 Impact factor: 4.749
Authors: Enrico Romagnoli; Maria De Vita; Francesco Burzotta; Bernardo Cortese; Giuseppe Biondi-Zoccai; Francesco Summaria; Roberto Patrizi; Chiara Lanzillo; Valerio Lucci; Caterina Cavazza; Fabio Tarantino; Giuseppe M Sangiorgi; Ernesto Lioy; Filippo Crea; Sunil V Rao; Carlo Trani Journal: Am Heart J Date: 2013-10-10 Impact factor: 4.749
Authors: Sanket S Dhruva; Joseph S Ross; Bobak J Mortazavi; Nathan C Hurley; Harlan M Krumholz; Jeptha P Curtis; Alyssa Berkowitz; Frederick A Masoudi; John C Messenger; Craig S Parzynski; Che Ngufor; Saket Girotra; Amit P Amin; Nilay D Shah; Nihar R Desai Journal: JAMA Date: 2020-02-25 Impact factor: 56.272
Authors: Jerry D Estep; Andrea M Cordero-Reyes; Arvind Bhimaraj; Barry Trachtenberg; Nashwa Khalil; Matthias Loebe; Brian Bruckner; Carlos M Orrego; Jean Bismuth; Neal S Kleiman; Guillermo Torre-Amione Journal: JACC Heart Fail Date: 2013-09-11 Impact factor: 12.035
Authors: Mamas A Mamas; Simon G Anderson; Karim Ratib; Helen Routledge; Ludwig Neyses; Douglas G Fraser; Iain Buchan; Mark A de Belder; Peter Ludman; Jim Nolan Journal: Am Heart J Date: 2014-03-27 Impact factor: 4.749